Key result
Angiotensin II infusion suppressed plasma renin activity in men with a negative family history, but only suppressed it in those with a positive family history after irbesartan.
Why the study?
Does angiotensin II infusion suppress plasma renin activity differently in normotensive men with a positive versus negative family history of hypertension, and is this corrected by AT1 receptor blockade?
Does angiotensin II infusion suppress plasma renin activity differently in normotensive men with a positive versus negative family history of hypertension, and is this corrected by AT1 receptor blockade?
Normotensive individuals with a family history of hypertension exhibit a defective suppression of plasma renin activity by angiotensin II, which can be corrected by AT1 receptor blockade with irbesartan.
Answers are grounded in this paper and cite their sources.
Suggests AT1-dependent renin dysregulation in familial hypertension risk; hypothesis-generating, requiring larger trials before clinical application.
The renin-angiotensin system is implicated in the pathophysiology of hypertension. Renin release is regulated by a number of factors, including circulating Ang II (angiotensin II), the so-called short feedback loop. The aim of the present study was to investigate the responsiveness of circulating Ang II on PRA (plasma renin activity) in normotensive subjects with a PFH or NFH (positive or negative family history of hypertension respectively). PRA, renal haemodynamics and urinary sodium excretion were measured during infusion of Ang II without and with pretreatment with the AT1 (Ang II type 1) receptor blocker irbesartan. Normotensive men with a PFH (n=13) and NFH (n=10), with a mean age of 38 years, were given on different occasions intravenous Ang II infusions of 0.1, 0.5 and 1.0 ng.kg-1 of body weight.min-1 before and after pretreatment with 150 mg of irbesartan once a day for 5 consecutive days. RPF (renal plasma flow) and GFR (glomerular filtration rate) were also measured. Before Ang II infusion, the PFH and NFH groups did not differ with respect to BP (blood pressure), body mass index, PRA, RBF (renal blood flow) or urinary sodium. There was no difference in BP or renal haemodynamic response to the highest Ang II dose between the groups. PRA declined with the highest Ang II dose (P<0.01) in subjects with a NFH, but not in subjects with a PFH. After treatment with irbesartan when Ang II had no effect on BP in either group, Ang II also suppressed PRA in subjects with a PFH (P<0.01), and the difference between the groups at baseline was thus eliminated. In conclusion, these findings indicate that subjects with a PFH have a defective Ang II suppression of PRA, which is corrected by AT1 receptor blockade.
No takes yet. Share an insight, caveat, or question.
Herlitz et al. (2005) studied Family history of hypertension (n=23). Angiotensin II infusion and irbesartan vs. Negative family history group / Baseline was evaluated on Plasma renin activity (PRA) (p=<0.01). Angiotensin II infusion suppressed plasma renin activity in men with a negative family history, but only suppressed it in those with a positive family history after irbesartan.
Synapse has enriched 10 related papers. Consider them for comparative context: